Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 3/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
| ▸ | MME | P08473 | 7/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 6/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16486901 | 0.87 | MMP12 (0.58) | MMP12MMP2MMP9MMP13MMP14 | |
| SCHEMBL27800230 | 0.78 | FDFT1 (0.54) | MMP12MMP2MMP9MMP13MMP14 | |
| SCHEMBL18019606 | 0.78 | FDFT1 (0.54) | MMP12MMP2MMP9MMP13MMP14 | |
| SCHEMBL1073143 | 0.77 | TSHR (0.68) | TSHR | |
| SCHEMBL264775 | 0.77 | TSHR (0.68) | TSHR | |
| SCHEMBL473576 | 0.77 | TSHR (0.68) | TSHR | |
| SCHEMBL12670558 | 0.77 | TSHR (0.68) | TSHR | |
| Felbinac SCHEMBL28284704 | 0.77 | ABCC4 (0.68) | TSHRFFAR1 | |
| Phosphine SCHEMBL27480220 | 0.76 | TSHR (0.66) | TSHR | |
| SCHEMBL11838769 | 0.74 | MMP12 (0.54) | MMP12MMP2MMP9MMP13MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 555 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| US-20070211212-A1 | Eye state sensor | PHARMACIA CORPORATION | 2007-09-13 | — | — | US | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20020107238-A1 | Topical antibiotic composition for treatment of eye infection | PHARMACIA & UPJOHN COMPANY | 2002-08-08 | — | — | US | claimed |
| WO-2002030395-A1 | TOPICAL ANTIBIOTIC COMPOSITION FOR TREATMENT OF EYE INFECTION | PHARMACIA & UPJOHN COMPANY (US) | 2002-04-18 | — | — | WO | claimed |
| US-20020035264-A1 | Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug | PHARMACIA & UPJOHN COMPANY | 2002-03-21 | — | — | US | claimed |
| WO-2002005815-A1 | OPHTHALMIC FORMULATION OF A SELECTIVE CYCLOOXYGENASE-2 INHIBITORY DRUG | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-24 | — | — | WO | claimed |
| WO-1998029069-A2 | METHOD FOR CHANGING THE REFRACTIVE POWER OF AN EYE | ALLERGAN SALES, INC. (US) | 1998-07-09 | — | — | WO | claimed |
| US-5360611-A | Antiinflammatory | ALCON LABORATORIES, INC. (US) | 1994-11-01 | — | — | US | claimed |
| US-5271939-A | Pharmaceutical compositions and methods of treatment to prevent and treat corneal scar formation produced by laser irradiation | ALCON LABORATORIES, INC. (US) | 1993-12-21 | — | — | US | claimed |
| EP-0105635-B1 | NONIRRITATING AQUEOUS OPHTHALMIC COMPOSITIONS COMFORT FORMULATION FOR OCULAR THEREPEUTIC AGENTS | ALCON LABORATORIES, INC. (US) | 1990-04-04 | — | — | EP | claimed |
| US-4559343-A | ANTIINFLAMMATORY AGENT WITH XANTHINE DERIVATIVE | ALCON LABORATORIES, INC. (US) | 1985-12-17 | — | — | US | claimed |
| EP-0105635-A2 | Nonirritating aqueous ophthalmic compositions comfort formulation for ocular therepeutic agents | ALCON LABORATORIES, INC. (US) | 1984-04-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107238-A1 | Topical antibiotic composition for treatment of eye infection | CUTA, DEK, LPXN | MMP12 2111/4885MMP2 141/4885MMP9 89/4885 |
| US-20020035264-A1 | Ophthalmic formulation of a selective cyclooxygenase-2 inhibitory drug | PTGS2, PTGES2, PTGS1 | MMP12 452/4885MMP2 156/4885MMP9 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.